399 related articles for article (PubMed ID: 25762693)
1. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
2. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.
Farmer LJ; Ledeboer MW; Hoock T; Arnost MJ; Bethiel RS; Bennani YL; Black JJ; Brummel CL; Chakilam A; Dorsch WA; Fan B; Cochran JE; Halas S; Harrington EM; Hogan JK; Howe D; Huang H; Jacobs DH; Laitinen LM; Liao S; Mahajan S; Marone V; Martinez-Botella G; McCarthy P; Messersmith D; Namchuk M; Oh L; Penney MS; Pierce AC; Raybuck SA; Rugg A; Salituro FG; Saxena K; Shannon D; Shlyakter D; Swenson L; Tian SK; Town C; Wang J; Wang T; Wannamaker MW; Winquist RJ; Zuccola HJ
J Med Chem; 2015 Sep; 58(18):7195-216. PubMed ID: 26230873
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K
J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis.
Shan S; Zhou Y; Yu J; Yang Q; Pan D; Wang Y; Li L; Zhu J; Zhang Y; Huang S; Li Z; Ning Z; Xin L; Lu X
Int Immunopharmacol; 2019 Dec; 77():105914. PubMed ID: 31634789
[TBL] [Abstract][Full Text] [Related]
7. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
[TBL] [Abstract][Full Text] [Related]
8. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.
Vazquez ML; Kaila N; Strohbach JW; Trzupek JD; Brown MF; Flanagan ME; Mitton-Fry MJ; Johnson TA; TenBrink RE; Arnold EP; Basak A; Heasley SE; Kwon S; Langille J; Parikh MD; Griffin SH; Casavant JM; Duclos BA; Fenwick AE; Harris TM; Han S; Caspers N; Dowty ME; Yang X; Banker ME; Hegen M; Symanowicz PT; Li L; Wang L; Lin TH; Jussif J; Clark JD; Telliez JB; Robinson RP; Unwalla R
J Med Chem; 2018 Feb; 61(3):1130-1152. PubMed ID: 29298069
[TBL] [Abstract][Full Text] [Related]
9. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY
Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982
[TBL] [Abstract][Full Text] [Related]
10. Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice.
Lin TH; Hegen M; Quadros E; Nickerson-Nutter CL; Appell KC; Cole AG; Shao Y; Tam S; Ohlmeyer M; Wang B; Goodwin DG; Kimble EF; Quintero J; Gao M; Symanowicz P; Wrocklage C; Lussier J; Schelling SH; Hewet AG; Xuan D; Krykbaev R; Togias J; Xu X; Harrison R; Mansour T; Collins M; Clark JD; Webb ML; Seidl KJ
Arthritis Rheum; 2010 Aug; 62(8):2283-93. PubMed ID: 20506481
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
He L; Pei H; Lan T; Tang M; Zhang C; Chen L
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
13. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
14. VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
Zetterberg C; Maltais F; Laitinen L; Liao S; Tsao H; Chakilam A; Hariparsad N
Drug Metab Dispos; 2016 Aug; 44(8):1286-95. PubMed ID: 27298338
[TBL] [Abstract][Full Text] [Related]
15. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.
Chang BY; Zhao F; He X; Ren H; Braselmann S; Taylor V; Wicks J; Payan DG; Grossbard EB; Pine PR; Bullard DC
J Immunol; 2009 Aug; 183(3):2183-92. PubMed ID: 19596999
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.
Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D
Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
[TBL] [Abstract][Full Text] [Related]
18. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model.
Ito M; Yamazaki S; Yamagami K; Kuno M; Morita Y; Okuma K; Nakamura K; Chida N; Inami M; Inoue T; Shirakami S; Higashi Y
J Pharmacol Sci; 2017 Jan; 133(1):25-33. PubMed ID: 28117214
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.
Van Rompaey L; Galien R; van der Aar EM; Clement-Lacroix P; Nelles L; Smets B; Lepescheux L; Christophe T; Conrath K; Vandeghinste N; Vayssiere B; De Vos S; Fletcher S; Brys R; van 't Klooster G; Feyen JH; Menet C
J Immunol; 2013 Oct; 191(7):3568-77. PubMed ID: 24006460
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.
Pei H; He L; Shao M; Yang Z; Ran Y; Li D; Zhou Y; Tang M; Wang T; Gong Y; Chen X; Yang S; Xiang M; Chen L
Sci Rep; 2018 Mar; 8(1):5273. PubMed ID: 29588471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
